Mrs Julie Marie Haegele, LPN in Annadale, MN - Licensed Practical Nurse

Mrs Julie Marie Haegele, LPN is a Licensed Practical Nurse based in Annadale, Minnesota. Mrs Julie Marie Haegele is licensed to practice in Minnesota (license number L0324757) and her current practice location is 4986 Cty Rd 6 Nw, Annadale, Minnesota. She can be reached at her office (for appointments etc.) via phone at (320) 274-8060.

NPI number for Mrs Julie Marie Haegele is 1376704122 and her current mailing address is Po Box 705, 4986 Cty Rd 6 Nw, Annadale, Minnesota. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1376704122.

Contact Information

	Mrs Julie Marie Haegele, LPN
	4986 Cty Rd 6 Nw, Annadale, MN 55358
	(320) 274-8060
	(320) 274-3123

Provider's Profile

Full Name	Mrs Julie Marie Haegele
Gender	Female
Speciality	Licensed Practical Nurse
Location	4986 Cty Rd 6 Nw, Annadale, Minnesota
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1376704122
Provider Enumeration Date: 06/24/2008
Last Update Date: 06/24/2008

Medical Identifiers

Medical identifiers for Mrs Julie Marie Haegele such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1376704122	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
164W00000X	Licensed Practical Nurse	L0324757 (Minnesota)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mrs Julie Marie Haegele is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mrs Julie Marie Haegele, LPN Po Box 705, 4986 Cty Rd 6 Nw, Annadale, MN 55358 Ph: (320) 274-8060	Mrs Julie Marie Haegele, LPN 4986 Cty Rd 6 Nw, Annadale, MN 55358 Ph: (320) 274-8060

News Archive

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the statistically significant top-line results released by its licensee, Tarsa Therapeutics, validate its proprietary oral peptide drug delivery technology.

Health care reform should ensure coverage is more affordable: America's Health Insurance Plans

"We agree the status quo is not sustainable. That is why health plans last year did something industries rarely do: stepped up and offered solutions to address the health care concerns raised by the American people.

FDA approves combination immunotherapy for treatment of kidney cancer

The standard of care for kidney cancer patients continues to improve. The U.S. Food and Drug Administration granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer.

Study compares three new methods to study disorders of consciousness

Disorders of consciousness such as coma or a vegetative state caused by severe brain injury are poorly understood and their diagnosis has relied mainly on patient responses and measures of brain activity. However, new functional and imaging-based diagnostic tests that measure communication and signaling between different brain regions may provide valuable information about the potential for consciousness in patients unable to communicate. These innovative approaches are described and compared in a Review article in the groundbreaking neuroscience journal Brain Connectivity, a bimonthly peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

Study offers hope for a new therapeutic option for patients with severe asthma

A new monoclonal antibody therapy shows promise in offering an alternative treatment for patients suffering from moderate-to-severe asthma. Research led by Michael E. Wechsler, MD, MMSc, director of the National Jewish Health Cohen Family Asthma Institute, found that itepekimab was safe and effective in a phase 2 trial published online today in the New England Journal of Medicine.

Mrs Julie Marie Haegele, LPN - Licensed Practical Nurse in Annadale, MN